Immunisation against meningococcus B: the case of Spain

The Lancet

Volumn 382, Issue 9904, 2013, Pages 1552-1553

  Martinón Torres, Federico ^a  

^a Santiago University Clinical Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

COST BENEFIT ANALYSIS; HEALTH PROGRAM; HUMAN; IMMUNIZATION; LETTER; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SPAIN;

EID: 84887240468     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62323-5     Document Type: Letter

References (4)

1. Moxon R, Snape MD. The price of prevention: what now for immunisation against meningococcus B? Lancet 2013; 382: 369-70.
2. AEMPS (Spanish Agency on Drugs and Health Products). Report on therapeutic utility of Bexsero (in Spanish). http://www.aemps.gob.es/ medicamentosUsoHumano/vacunas/infoUtilTerapeutica/docs/infUtilTerap-Bexsero.pdf (accessed Oct 11, 2013).
3. Limia A, Navarro Alonso JA, Vázquez J, Cano R, Salmerón F. Vaccine against invasive meningococcal disease by B serogroup and its possible use in publich health, June 2013 report (in Spanish). http://www.msssi.gob.es/ profesionales/saludPublica/prevPromocion/vacunaciones/docs/MenB.pdf (accessed Oct 11, 2013).
4. Cano Portero R, Garrido Estepa M. Meningococcal disease in Spain: analysis of 2009-2010 (in Spanish). http://revista.isciii.es/index.php/bes/rt/ printerFriendly/423/452 (accessed Oct 8, 2013).